Search clinical trials for: 225Ac-J591

Total 61 results

Weill Medical College of Cornell University

Recruiting

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Prostate Cancer

United States
Weill Medical College of Cornell University
POINT Biopharma

Suspended

Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Weill Medical College of Cornell University

Recruiting

Re-treatment 225Ac-J591 for mCRPC

Prostate Cancer

United States
Weill Medical College of Cornell University

Completed

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Gliomas

United States
Weill Medical College of Cornell University

Completed

Neoadjuvant J591 Treatment for Prostate Cancer

Prostate Cancer

United States
Weill Medical College of Cornell University
National Cancer Institute (NCI); United States Department of Defense; National... and other collaborators

Completed

Phase I Trial of 225Ac-J591 in Patients With mCRPC

Prostate Cancer

United States
Erasmus Medical Center
Dutch Cancer Society

Recruiting

Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy (225AcPSMAI&T)

Prostatic Neoplasms, Castration-Resistant

Netherlands
Weill Medical College of Cornell University

Completed

Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

Prostate Cancer

United States
Modulation Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Uveal Melanoma | Metastatic

United States
TYK Medicines, Inc

Recruiting

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

Healthy Volunteers

China
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
Fusion Pharmaceuticals Inc.

Terminated

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Liver Cancer | Bladder Carcinoma | Susceptible FGFR3 Genetic Alterations | FGFR3 | FGFR3 Overexpression | FGFR3 Receptor | FGFR3 Protein Overexpression

United States, Australia
Zhejiang ACEA Pharmaceutical Co. Ltd.

Recruiting

A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

AML, Adult

China
TYK Medicines, Inc

Active, not recruiting

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University

Completed

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Glioblastoma

United States
TYK Medicines, Inc

Completed

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

NSCLC

China
Neuren Pharmaceuticals Limited

Completed

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

Healthy Volunteers

Australia
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; United States Department of Defense

Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
Fusion Pharmaceuticals Inc.
AstraZeneca

Recruiting

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal Carcinoma

United States, Canada
Merck Sharp & Dohme LLC

Terminated

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Coronavirus Disease (COVID-19)

United States, Austria, Belgium
Weill Medical College of Cornell University
United States Department of Defense

Active, not recruiting

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Prostate Cancer

United States
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
Weill Medical College of Cornell University

Completed

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Prostate Cancer

United States
Weill Medical College of Cornell University

Completed

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

Prostate Cancer

United States
TYK Medicines, Inc

Completed

A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Healthy Volunteers

China
Weill Medical College of Cornell University

Terminated

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Novartis Pharmaceuticals

Recruiting

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome (AS-001)

Angelman Syndrome

Australia
Neuren Pharmaceuticals Limited

Active, not recruiting

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001) (PMS-001)

Phelan-McDermid Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers

Metastatic Cancer | Advanced Cancer

United States
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) (PTHS-001)

Pitt Hopkins Syndrome

United States
Neuren Pharmaceuticals Limited

Recruiting

An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001)

Prader-Willi Syndrome

United States
BTS International
Clinimark, LLC; Guangdong Transtek Medical Electronics Co., Ltd.

Completed

Clinical Trial of Blood Pressure Monitor in Conformance With the ANSI/AAMI ISO 81060-2 Standard (CT_1591-A)

Blood Pressure

United States
Weill Medical College of Cornell University
Convergent Therapeutics, Inc.

Withdrawn

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer (ACTION)

Prostate Cancer Metastatic

United States
BZL Biologics

Completed

Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2

Prostatic Neoplasms

United States
TYK Medicines, Inc

Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NSCLC | Brain Metastases | EGFR Activating Mutation

China
Revance Therapeutics, Inc.

Completed

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Torticollis (Spasmodic)

United States
Institut Pasteur
Coalition for Epidemic Preparedness Innovations; Themis Bioscience GmbH

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)

COVID-19

Belgium, France
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID); CONRAD

Completed

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

HIV Infections

United States
Weill Medical College of Cornell University

Completed

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Prostate Cancer

United States
Stanford University

Recruiting

The Role of Secondary Bile Acids in Intestinal Inflammation

Ulcerative Colitis | Pouchitis

United States
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection

United States, Germany
Merck Sharp & Dohme LLC

Not yet recruiting

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

HIV | Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

HIV-1 Infection

United States, Israel, South Africa
Merck Sharp & Dohme LLC

Completed

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Human Immunodeficiency Virus (HIV) Infection

United States
Merck Sharp & Dohme LLC

Withdrawn

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Human Immunodeficiency Virus (HIV) Infections

Search clinical trials for: 225Ac-J591

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations